-
1st OTC continuous glucose monitor enters US market
For $99, U.S. customers can now purchase a 30-day supply of the nation's first over-the-counter continuous glucose monitoring system. -
Pharmacies still aren't ready for DSCSA
Several national pharmacy associations are asking the FDA to offer a blanket exemption, waiver or exception from the Drug Supply Chain Security Act. -
Sandoz plans 2030 US launch for Ozempic generic
Swiss pharmaceutical company Sandoz is launching a generic semaglutide, the main ingredient of Ozempic, in the U.S. when the market opens in 2030, Bloomberg reported Sept. 3. -
6 drugs now in shortage
The sole suppliers for a few medications, including a Parkinson's disease therapy, are reporting new drug shortages. -
FDA approves mpox vaccine requiring 15 'vigorous' jabs
Emergent BioSolutions' smallpox vaccine is now FDA-approved for the prevention of mpox, the drugmaker said Aug. 29. -
Meijer opens pharmacy inside Corewell hospital
Meijer, a grocery store chain with more than 500 locations, has opened its second retail pharmacy inside a Corewell Health hospital. -
Lawmaker accuses CVS, Cigna, UnitedHealth execs of making false statements to Congress
A federal lawmaker investigating pharmacy benefit managers is accusing top executives from CVS Health, Cigna Group and UnitedHealth Group of making false statements during a committee hearing in July. -
6 updates on weight loss drugs
Physicians are increasingly comfortable prescribing weight loss drugs such as Wegovy and Zepbound as new potential uses emerge, but cost and access challenges remain persistent hurdles. -
Pharmacists slam J&J's plan to end upfront 340B discounts
The American Society of Health-System Pharmacies is speaking out against Johnson & Johnson's plan to drop upfront discounts for some 340B drugs. -
Pfizer goes direct to consumer
Following a similar move from Eli Lilly, Pfizer launched a platform Aug. 27 to sell migraine, COVID-19 and flu products directly to consumers. -
Eli Lilly selling Zepound vials at 50% discount: 4 notes
Eli Lilly has started selling single-dose vials of its blockbuster weight loss drug Zepbound for roughly half of its usual monthly list price. -
FDA tightens use of preventive COVID drug
After about 18 months since the FDA greenlit preventive COVID-19 medication Pemgarda for emergency use, the agency has tweaked its decision. -
Nearly half of US counties have a pharmacy desert: Study
In 46% of U.S. counties, there are no retail pharmacies within 10 miles, according to a study from The Ohio State University. -
How Michigan Medicine is addressing pharmacy deserts
Ann Arbor-based Michigan Medicine is bolstering staff at five of its outpatient pharmacies as Rite Aid closes all its stores in the state, according to an Aug. 25 report from MLive. -
After rejected drug approval, FDA probes drugmaker
The FDA is investigating allegations of misconduct in Lykos Therapeutics' studies of its experimental MDMA drug, which failed to win agency approval in early August, according to The Wall Street Journal. -
J&J to drop upfront hospital discounts for some drugs
Johnson & Johnson plans to end upfront discounts for two drugs sold to disproportionate share hospitals under the 340B program, replacing them with a rebate application process, The Wall Street Journal reported Aug. 23. -
MetroHealth upped patient refill retention by 45% — here's how
MetroHealth has increased patients' refill retention rate from 35% to 80% — thanks to a few shifts in its operating model. -
FDA clears new COVID shots: 3 notes
The FDA signed off on updated mRNA COVID-19 vaccines from Pfizer and Moderna. The new shots target the KP.2 strain and are expected to be available at pharmacies, hospitals and clinics within a few days, the drugmakers said. -
10 common problems in pharmacies: Report
Staffing and scheduling issues contributed to the highest number of negative experiences reported by pharmacy professionals, according to the latest Pharmacy Workplace and Well-being Reporting released by the American Pharmacists Association. -
The PharmD applicant pool problem
Since the 2012-13 school year, pharmacy schools have seen fewer applicants for PharmD programs.
Page 12 of 50